Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Makaleler > Tam Makale · 2015
Yazarlar: Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem GÖKER, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss
The Lancet Oncology, Uluslararası, Wos, 2015, cilt 16, ss 897-907